Key facts
- Abram Scientific’s last known valuation is $35.0M (Feb 2026).
- It has raised $11.8M; the latest was Later Stage VC ($11.8M) in Feb 2026.
- Notable investors include US National Science Foundation, United States Department of War, Octapharma.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Abram Scientific
- ·The full record, as it builds
Funding rounds
No funding rounds for Abram Scientific are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Abram Scientific
Developer of a coagulation diagnostic platform designed for the diagnosis and characterisation of coagulation-related disorders. The company offers a point-of-care meter and single-use diagnostic test card that utilises proprietary technology for the measurement of blood viscoelasticity and density, characterising the entire blood coagulation cascade from blood clot formation to lysis, enabling healthcare professionals to detect blood clotting or bleeding disorders and guiding the use of therapy for optimal coagulation management.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2011
- Employees
- 6
- Website
- abramscientific.com/
- Ownership
- Privately Held (backing)
Abram Scientific doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Abram Scientific shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Abram Scientific in its N-PORT filings yet. We sweep new filings monthly.